Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) EVP Fady Ibraham Malik sold 3,500 shares of the business's stock in a transaction dated Tuesday, May 5th. The shares were sold at an average price of $77.37, for a total transaction of $270,795.00. Following the completion of the sale, the executive vice president directly owned 153,902 shares of the company's stock, valued at approximately $11,907,397.74. This trade represents a 2.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Fady Ibraham Malik also recently made the following trade(s):
- On Tuesday, April 21st, Fady Ibraham Malik sold 3,500 shares of Cytokinetics stock. The shares were sold at an average price of $65.69, for a total transaction of $229,915.00.
- On Tuesday, April 7th, Fady Ibraham Malik sold 4,500 shares of Cytokinetics stock. The shares were sold at an average price of $65.11, for a total transaction of $292,995.00.
- On Tuesday, March 17th, Fady Ibraham Malik sold 12,033 shares of Cytokinetics stock. The shares were sold at an average price of $62.15, for a total transaction of $747,850.95.
- On Monday, March 9th, Fady Ibraham Malik sold 2,907 shares of Cytokinetics stock. The shares were sold at an average price of $60.72, for a total transaction of $176,513.04.
Cytokinetics Price Performance
Cytokinetics stock opened at $77.09 on Wednesday. The stock has a market cap of $9.58 billion, a price-to-earnings ratio of -11.81 and a beta of 0.38. Cytokinetics, Incorporated has a 1 year low of $29.31 and a 1 year high of $80.20. The firm has a 50-day moving average of $64.00 and a two-hundred day moving average of $63.63.
Cytokinetics (NASDAQ:CYTK - Get Free Report) last released its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported ($1.67) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($1.67). The company had revenue of $19.36 million during the quarter, compared to analysts' expectations of $8.52 million. Cytokinetics's quarterly revenue was up 1112.5% on a year-over-year basis. During the same period last year, the firm earned ($1.36) earnings per share. Research analysts expect that Cytokinetics, Incorporated will post -6.31 earnings per share for the current year.
Key Headlines Impacting Cytokinetics
Here are the key news stories impacting Cytokinetics this week:
- Positive Sentiment: Topline Phase‑3 win — the ACACIA‑HCM pivotal trial of aficamten met both dual primary endpoints with supportive secondary data, a major de‑risking event that expands the drug’s commercial and regulatory potential. ACACIA‑HCM Topline Results
- Positive Sentiment: Strong initial commercial uptake — management reported U.S. launch demand for MYQORZO with ~275 HCPs prescribing to an estimated ~680 patients in Q1 and ~$4.8M in partial‑quarter net product revenue; company also reported ~ $1.1B in cash, which supports launch and development. Q1 2026 Financial Results & Business Update
- Positive Sentiment: Analyst upgrades — Needham (and other firms) raised price targets, increasing buy‑side enthusiasm and providing upward analyst momentum for shares. Analyst Price Target Raises
- Neutral Sentiment: Q1 reported EPS loss of ($1.67) matched expectations while revenue materially beat consensus ($19.36M vs ~$8.5M), signaling revenue strength but continued GAAP losses as the company scales launch and development. Q1 Loss, Revenue Beat
- Neutral Sentiment: Insider sales disclosed — EVP Andrew Callos and EVP Fady Malik sold shares under pre‑arranged Rule 10b5‑1 plans (large planned disposals rather than ad‑hoc exits); commonly viewed as neutral but can prompt short‑term investor attention. Malik SEC Form 4 Callos SEC Form 4
- Negative Sentiment: Planned $650M underwritten common stock offering — while proceeds would fund commercialization and development, the offering presents near‑term dilution risk that can weigh on the share price until completed. Proposed Public Offering
Institutional Inflows and Outflows
Institutional investors have recently added to or reduced their stakes in the business. Millennium Management LLC grew its position in shares of Cytokinetics by 361.9% in the 1st quarter. Millennium Management LLC now owns 287,901 shares of the biopharmaceutical company's stock worth $11,571,000 after buying an additional 225,576 shares during the last quarter. Cetera Investment Advisers grew its position in shares of Cytokinetics by 12.4% in the 2nd quarter. Cetera Investment Advisers now owns 6,635 shares of the biopharmaceutical company's stock worth $219,000 after buying an additional 731 shares during the last quarter. EverSource Wealth Advisors LLC grew its position in shares of Cytokinetics by 723.7% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 766 shares of the biopharmaceutical company's stock worth $25,000 after buying an additional 673 shares during the last quarter. Gabelli Funds LLC grew its position in shares of Cytokinetics by 29.4% in the 2nd quarter. Gabelli Funds LLC now owns 8,410 shares of the biopharmaceutical company's stock worth $278,000 after buying an additional 1,910 shares during the last quarter. Finally, California Public Employees Retirement System grew its position in shares of Cytokinetics by 10.8% in the 2nd quarter. California Public Employees Retirement System now owns 142,602 shares of the biopharmaceutical company's stock worth $4,712,000 after buying an additional 13,911 shares during the last quarter.
Wall Street Analysts Forecast Growth
A number of research firms have commented on CYTK. Jefferies Financial Group reissued a "buy" rating and set a $90.00 target price on shares of Cytokinetics in a research report on Friday, January 9th. Bank of America reissued a "neutral" rating on shares of Cytokinetics in a research report on Wednesday, February 25th. Royal Bank Of Canada raised their target price on shares of Cytokinetics from $95.00 to $101.00 and gave the company an "outperform" rating in a research report on Friday, February 20th. Wells Fargo & Company began coverage on shares of Cytokinetics in a research report on Friday, April 10th. They set an "overweight" rating and a $95.00 target price on the stock. Finally, Needham & Company LLC raised their target price on shares of Cytokinetics from $85.00 to $102.00 and gave the company a "buy" rating in a research report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Cytokinetics presently has a consensus rating of "Moderate Buy" and a consensus target price of $92.10.
Get Our Latest Stock Report on Cytokinetics
Cytokinetics Company Profile
(
Get Free Report)
Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.
The company's most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
